AgeX Therapeutics, Inc (AGE) is a leading biotechnology business based in the US. It opened the day at $0.8379 after a previous close of $0.798. During the day the price has varied from a low of $0.7753 to a high of $0.87. The latest price was $0.795 (25 minute delay). AgeX Therapeutics is listed on the NYSE MKT and employs 17 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, AgeX Therapeutics's share price has had significant positive movement.
Its last market close was $1.78, which is 25.84% up on its pre-crash value of $1.32 and 137.33% up on the lowest point reached during the March crash when the shares fell as low as $0.75.
If you had bought $1,000 worth of AgeX Therapeutics shares at the start of February 2020, those shares would have been worth $625.96 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,358.78.
|52-week range||$0.68 - $2.59|
|50-day moving average||$1.1227|
|200-day moving average||$0.9893|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.318|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2020-10-15)||-54.57%|
|1 month (2020-09-25)||-5.36%|
|3 months (2020-07-24)||-40.23%|
|6 months (2020-04-24)||-7.45%|
|1 year (2019-10-25)||-49.36%|
|Revenue TTM||$1.9 million|
|Gross profit TTM||$1.5 million|
|Return on assets TTM||-98.37%|
|Return on equity TTM||-453.02%|
|Market capitalisation||$62.6 million|
TTM: trailing 12 months
There are currently 1.4 million AgeX Therapeutics shares held short by investors – that's known as AgeX Therapeutics's "short interest". This figure is 0.9% down from 1.4 million last month.
There are a few different ways that this level of interest in shorting AgeX Therapeutics shares can be evaluated.
AgeX Therapeutics's "short interest ratio" (SIR) is the quantity of AgeX Therapeutics shares currently shorted divided by the average quantity of AgeX Therapeutics shares traded daily (recently around 173190.71518193). AgeX Therapeutics's SIR currently stands at 7.97. In other words for every 100,000 AgeX Therapeutics shares traded daily on the market, roughly 7970 shares are currently held short.
However AgeX Therapeutics's short interest can also be evaluated against the total number of AgeX Therapeutics shares, or, against the total number of tradable AgeX Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AgeX Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 AgeX Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.065% of the tradable shares (for every 100,000 tradable AgeX Therapeutics shares, roughly 65 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AgeX Therapeutics.
Find out more about how you can short AgeX Therapeutics stock.
We're not expecting AgeX Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
AgeX Therapeutics's shares were split on a 15:16 basis on 6 May 2015. So if you had owned 16 shares the day before before the split, the next day you'd have owned 15 shares. This wouldn't directly have changed the overall worth of your AgeX Therapeutics shares – just the quantity. However, indirectly, the new 6.7% higher share price could have impacted the market appetite for AgeX Therapeutics shares which in turn could have impacted AgeX Therapeutics's share price.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.
Everything we know about the Virpax Pharmaceuticals IPO, plus information on how to buy it.
Everything we know about the Vivos Therapeutics IPO, plus information on how to buy it.
Everything we know about the Kiromic Biopharma IPO, plus information on how to buy it.
Everything we know about the Codiak BioSciences IPO, plus information on how to buy it.
Everything we know about the Triller IPO, plus information on how to buy it.
Everything we know about the Eastern Bank IPO, plus information on how to buy it.
Everything we know about the Wish IPO, plus information on how to buy it.
Everything we know about the MINISO Group Holding Limited IPO, plus information on how to buy it.
Everything we know about the Playboy IPO, plus information on how to buy it.
Everything we know about the iHuman IPO, plus information on how to buy it.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.